INTRODUCTION
This is the report of a conference held December 6 through 9, 1977, at the Kroc Foundation headquarters in Santa Ynez, California. The Lawson Wilkins Pediatric Endocrine Society and the National Institute of Child Health and Human Development cosponsored the meeting with the Foundation.
The conference was conceived at a time when prescribing estrogens had become controversial among physicians and the public. The treatment of tall girls to limit growth was sufficiently newsworthy to appear as an article in the New York Times Magazine. The occurrence of adenocarcinoma in the daughters of women treated prenatally with diethylstilbestrol was the subject of congressional hearings. It seemed the right time to bring together experts on the risks and benefits of prescribing estrogens to analyze what was known on the subject and to make recommendations on the use of estrogens in treating the young.
The publication includes the presentations at the conference, reports of the general discussions, and a summation of conclusion and recommendations. An article is included by Dr. Zev Rosenwaks and colleagues that was not presented but seemed appropriate to the symposium. The reports of the general discussion were made by Dr. Allan Root, University of South Florida. The final summation was drafted by a committee composed of Drs. Conte, Crawford, Gurpide, Levine, New, and Root, and was submitted for comment to all the participants. Carole Bergstein was copy editor. I wish to thank all these people for their help.




